Skip to main content

Inflammatory Bowel Disease clinical trials at UCLA

4 in progress, 2 open to eligible people

Showing trials for
  • Dietary Composition in Crohn's Disease

    open to eligible people ages 18-75

    Patients with inflammatory bowel disease (IBD) often have narrowed microbial diversity and altered composition and function of the gut microbiome. We anticipate the anti-inflammatory diet, when compared with the usual diet, to produce favorable changes in these multi-omics profiles. These findings will provide insight into the interactions between diet and host biology, while providing clues on the mechanisms of diet therapy's effect and CD pathogenesis.

    Los Angeles, California

  • CDPATH™ to Help Manage and Treat Crohn's Disease

    open to eligible people ages 18 years and up

    CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

    Orange, California and other locations

  • Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

    Los Angeles, California and other locations

  • Hyperbaric Oxygen Therapy for Ulcerative Colitis

    Sorry, not yet accepting patients

    Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.

    Los Angeles, California and other locations

Our lead scientists for Inflammatory Bowel Disease research studies include .

Last updated: